<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241513</url>
  </required_header>
  <id_info>
    <org_study_id>H10-13</org_study_id>
    <nct_id>NCT01241513</nct_id>
  </id_info>
  <brief_title>Induced Changes in Ventilatory Responsiveness and Altitude Exposure</brief_title>
  <official_title>Modulation of Oxygen Sensor Reactivity to Mimic Altitude Acclimatization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United States Army Research Institute of Environmental Medicine</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United States Army Research Institute of Environmental Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if a drug (acetyl-cysteine or ACCY) can
      increase the amount of oxygen in your body at a high altitude of 11,500 feet. ACCY is
      approved by the Food and Drug Administration (FDA) as a treatment or antidote for Tylenol
      overdoses. Other forms of ACCY are also sold over-the-counter as nutritional supplements. In
      this study, the FDA-approved form of ACCY will be used &quot;off-label&quot; (meaning in a way not
      approved by the FDA).

      This study is being conducted by researchers from the United States Army Research Institute
      of Environmental Medicine (USARIEM). The study will take place in the Altitude Chamber
      located in the basement of USARIEM. A total of approximately 30 volunteers (men and women,
      military and civilians) will take part in the study. They can expect to be in the study for a
      minimum of a few hours each day for two weeks.

      The investigators hypothesize that ACCY will improve ventilation and oxygenation while at
      altitude.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine if modulating reduction/oxidation (redox) status through a
      temporary increase in the blood ratio of reduced-to-oxidized glutathione (i.e., GSH/GSSG)
      will increase carotid body chemosensitivity and thus increase ventilation and arterial oxygen
      saturation (SaO2) during 32 hours of hypobaric hypoxia exposure to 3500 m (11,500 feet). To
      that end, the study will use an FDA-approved oral suspension form of acetylcysteine (ACCY) to
      modulate blood redox status under controlled conditions in the Hypobaric Chamber Facility at
      the USARIEM. Up to 30 healthy, active-duty military personnel or civilians from the local
      area will be recruited. Two independent treatment groups (placebo and ACCY; up to 15 in each
      group) will be assessed at sea level and altitude using a between-group experimental design.
      The two groups will be matched as closely as possible by age, ventilation, fitness, and
      gender prior to treatment assignment. Neither the staff nor the volunteers will know the
      treatment received by the groups until the study is completed. Included will be only those
      men and women who: are 18 to 39 years old, were born at altitudes below 2100 m (7000 feet),
      are not taking medications that interfere with oxygen delivery and transport (includes
      sedatives, sleeping aids, tranquilizers and any medication that depresses ventilation,
      diuretics, alpha and beta blockers); and have no evidence of any physical, mental, and/or
      medical conditions that would make the proposed study relatively more hazardous. All
      volunteers will participate over the two-week long study period in multiple standardized
      assessments that include resting (e.g., resting ventilation, SaO2, questionnaires), sleeping
      (e.g., heart rate, SaO2) and exercise (e.g., steady-state and time-trial performance, SaO2)
      measurements. The potential risks to test volunteers include the risks associated with
      hypobaric hypoxia exposure (e.g., acute mountain sickness [AMS; headache, nausea, insomnia])
      and those associated with exercise (e.g., acute musculoskeletal strains and sprains,
      blisters). The investigators are not aware of any studies reporting problems during oral
      administration of ACCY in the doses or duration to be used in the present study. There are no
      direct benefits to the volunteers, except the knowledge of how well they performed at
      altitude and on the tests in which they participated. If the use of ACCY proves effective at
      altitude, then soldiers deployed to altitude in the future may have a means to beneficially
      increase ventilation and SaO2 in a manner similar to that experienced during natural altitude
      acclimatization.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Results of preliminary analyses showed no reason to continue the study
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial Oxygen Saturation</measure>
    <time_frame>Day 4 of treatment during acute altitude exposure</time_frame>
    <description>Finger Pulse Oximetry to measure arterial oxygen saturation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Effects of High Altitude</condition>
  <condition>Hypoxia</condition>
  <condition>Inadequate or Impaired Breathing Pattern or Ventilation</condition>
  <condition>Abnormal Blood Oxygen Pressure</condition>
  <arm_group>
    <arm_group_label>N-acetyl-L-Cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetyl-L-Cysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAC</intervention_name>
    <description>NAC provided to determine if beneficial at altitude</description>
    <arm_group_label>N-acetyl-L-Cysteine</arm_group_label>
    <other_name>NAC Accy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:

          -  Volunteers with the following criteria will be EXCLUDED from participation:

        Less than 18 years of age Greater than 39 years of age Born at altitudes greater than 2134
        m (7000 ft) Living in areas that are more than 1220 m (4,000 feet), or have traveled to
        areas that are more than 1220 m for more than a few days within the last 2 months.

        Abnormal [Hb]/Hct levels or presence of hemoglobin S Known allergies to sulfonamide
        derivatives Smokers who smoke more than 5 cigarettes per day Tobacco chewers If military,
        unable to pass the 2-mi run portion of the Army Physical Fitness Test, or equivalent If
        civilian, not currently running or exercising for at least 20 min/day, 3X/week in &quot;aerobic&quot;
        activities (e.g., running, biking. swimming, basketball, etc) If they do not want to walk
        or run multiple times for 1 to 3 hours on a treadmill Unable to meet the U.S. Army
        height/weight standards Not willing to sleep in bunk beds in a small room (8 feet by 8
        feet) with 1 to 3 other volunteers (male and/or female) for 3 nights. If they are
        claustrophobic Women who are pregnant or planning to conceive during the study period Women
        who are not willing to take urine pregnancy tests Not willing to drink an eight ounce
        solution of diet soda that may contain ACCY up to three times per day and then not willing
        to suck on a peppermint mint right after drinking the solution.

        Taking medications that interfere with oxygen delivery and transport (Includes sedatives,
        sleeping aids, tranquilizers and any medication that depresses ventilation, diuretics,
        alpha and beta blockers) Evidence of any physical, mental, and/or medical conditions that
        would make the proposed studies relatively more hazardous. Evidence of prior HAPE or HACE
        diagnosis Evidence of apnea or other sleeping disorders Evidence of asthma If applicable,
        unwilling to stop taking all supplements for the two weeks of participation If applicable,
        all medications (prescription or over-the-counter) must be approved by the PI, and/or the
        OMSO.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles S Fulco, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>United States Army Research Institute of Environmental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USARIEM</name>
      <address>
        <city>Natick</city>
        <state>Massachusetts</state>
        <zip>01760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <results_first_submitted>October 22, 2012</results_first_submitted>
  <results_first_submitted_qc>May 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 18, 2016</results_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glutathione</keyword>
  <keyword>redox status</keyword>
  <keyword>carotid body chemosensitivity</keyword>
  <keyword>ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Altitude Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2 participants withdrew prior to any testing</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>N-acetylcysteine</title>
          <description>Active drug group</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10">Study has been completed</participants>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-acetylcysteine (NAC)</title>
          <description>NAC</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" spread="3"/>
                    <measurement group_id="B2" value="22" spread="3"/>
                    <measurement group_id="B3" value="22" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Arterial Oxygen Saturation</title>
        <description>Finger Pulse Oximetry to measure arterial oxygen saturation</description>
        <time_frame>Day 4 of treatment during acute altitude exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Placebo (Diet soda only)</description>
          </group>
          <group group_id="O2">
            <title>NAC Group</title>
            <description>N-acetyl-L-Cysteine (800 mg T.I.D. in diet soda) for 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Oxygen Saturation</title>
          <description>Finger Pulse Oximetry to measure arterial oxygen saturation</description>
          <units>percentage of oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" spread="10"/>
                    <measurement group_id="O2" value="79" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events can not be reported by intervention group because the data were not unblinded for data analyse. Based on results of preliminary analyses, the blind was not broken to further parse out the data for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>NAC Group and Placebo Group</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomiting</sub_title>
                <description>determined to be due to caffeine withdrawal</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>acute mountain sickness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>expected adverse event; subject ended altitude exposure 4 hours early</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Delayed patella tendon soreness</sub_title>
                <description>recovered, finished study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>back soreness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>aggravation of previously undisclosed condition</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>foot soreness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>expected post exercise</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>knee injury</sub_title>
                <description>not study related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated due to results of preliminary analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Charles S Fulco, PI</name_or_title>
      <organization>USARIEM</organization>
      <phone>508 233-4893</phone>
      <email>charles.fulco@us.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

